logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Cabotegravir (oral tablet) in combination with rilpivirine (oral tablet) for the short-term treatment of HIV-1 infection

< Back

Cabotegravir (oral tablet) in combination with rilpivirine (oral tablet) for the short-term treatment of HIV-1 infection

Drugs

Infectious Disease and Immunisation

November 2019


Cabotegravir and rilpivirine tablets are in development as an oral lead-in therapy for a period of approximately one month as a short-term oral bridging treatment for Human Immunodeficiency Virus 1 (HIV-1) patients that are considered eligible for the long-acting injectable cabotegravir and rilpivirine therapy. HIV is a type of viral infection caused by a type of virus referred to as a retrovirus. HIV-1 is the most common and highly communicable type of HIV. HIV is a lifelong, chronic disease that nowadays can be managed with antiretroviral therapies (ARTs). Since HIV virus can quickly adapt and become resistant, a combination of ART drugs is normally used. Usually patients take between one and 4 or 6 tablets a day. Failing to do so will result in a weakened immune system and increased vulnerability to infections.
Cabotegravir is a type of ART designed to block the action of a specific viral enzyme that integrates the viral genome into the DNA of the host cell. Since integration is a vital step in retroviral replication, blocking it can halt further spread of the virus. Rilpivirine binds to and blocks a different type of enzyme that also prevents HIV from replicating. Short term treatment with oral formulations of cabotegravir and rilpivirine helps establishes the tolerability of treatment prior to the long-acting.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts